| Title |
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
|
|---|---|
| Published in |
BMC Cancer, February 2018
|
| DOI | 10.1186/s12885-018-3996-3 |
| Pubmed ID | |
| Authors |
Yu Qiao, Jihong Yang, Lili Liu, Yixin Zeng, Jie Ma, Jing Jia, Li Zhang, Xiaoguang Li, Peihong Wu, Wenchao Wang, Dongge Liu, Huan Chen, Yunbo Zhao, Huan Xi, Yao Wang |
| Abstract |
Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA. A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor. Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA. |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 14% |
| Professor > Associate Professor | 3 | 14% |
| Student > Bachelor | 2 | 10% |
| Student > Master | 2 | 10% |
| Student > Postgraduate | 2 | 10% |
| Other | 2 | 10% |
| Unknown | 7 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 43% |
| Computer Science | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Psychology | 1 | 5% |
| Engineering | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 8 | 38% |